Four key questions about metformin and cancer

BMC Biology

Volumn 12, Issue 1, 2014, Pages

  Chandel, Navdeep ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METFORMIN;

ANIMAL; HUMAN; INTERVIEW; MOUSE; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; METFORMIN; MICE; NEOPLASMS;

EID: 84924291112     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/s12915-014-0085-1     Document Type: Article

References (4)

1. Metabolism Diet and Disease 2014 [http://www.metabolism-diet-and-disease.com/]
2. Madiraju AK, Eion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI: Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014, 510:542-546.
3. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, Chandel NS: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 2014, 13:3.
4. Bridges HR, Jones AJ, Pollak MN, Hirst J: Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 2014, 462:475-487.